Last $0.01 USD
Change Today -0.0004 / -2.85%
Volume 2.2M
GNBT On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

generex biotechnology corp (GNBT) Snapshot

Open
$0.01
Previous Close
$0.01
Day High
$0.01
Day Low
$0.01
52 Week High
01/10/14 - $0.06
52 Week Low
12/18/14 - $0.01
Market Cap
11.3M
Average Volume 10 Days
2.7M
EPS TTM
$-0.0089
Shares Outstanding
789.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENEREX BIOTECHNOLOGY CORP (GNBT)

Related News

No related news articles were found.

generex biotechnology corp (GNBT) Related Businessweek News

No Related Businessweek News Found

generex biotechnology corp (GNBT) Details

Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It focuses on its proprietary technology for the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator. The company’s buccal delivery technology and products include Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using RapidMist hand-held aerosol spray applicator for the treatment of Type 1 and Type 2 diabetes. It is also involved in the research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune, and allergic diseases. In addition, the company is developing immunotherapeutic vaccine AE37 that is under Phase II clinical trial for patients with HER-2/neu positive breast cancer; and synthetic peptide vaccines against avian (H5N1) influenza, as well as vaccines against swine (H1N1) influenza. Further, it is developing synthetic peptide vaccines designed to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene that is in Phase II clinical trial for HER-2/neu positive breast cancer; in two Phase I clinical trials for prostate cancer and against avian influenza; and in Phase I clinical trial for breast or ovarian cancer. The company markets its products through collaborative arrangements with various companies worldwide. Generex Biotechnology Corporation was founded in 1983 and is based in Toronto, Canada.

8 Employees
Last Reported Date: 10/3/14
Founded in 1983

generex biotechnology corp (GNBT) Top Compensated Officers

Chief Executive Officer, President, General C...
Total Annual Compensation: $435.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $206.3K
Chief Operating Officer and Secretary
Total Annual Compensation: $206.3K
Compensation as of Fiscal Year 2014.

generex biotechnology corp (GNBT) Key Developments

Generex Biotechnology Corporation Announces Collaboration on Medicinal Cannabis

Generex Biotechnology Corporation announced that it has entered into a non-binding Letter of Intent (LOI) to license the company's proprietary RapidMist(TM) drug delivery technologies to CannScience Innovations Inc. (CannScience) for the delivery of medicinal cannabis derived products into the bloodstream through the buccal membrane. The RapidMist(TM) drug delivery platform administers medications directly into the mouth as a metered dose spray for rapid absorption by the buccal mucosa. Generex's most advanced product in development using RapidMist(TM) is Generex Oral-lyn(TM) for the treatment of diabetes mellitus. This co-development arrangement with CannScience is intended to develop products initially for the Canadian medical cannabis market. The LOI contemplates a significant royalty stream to Generex. Costs to develop, manufacture, and commercialize the products will be borne by CannScience.

Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons

Generex Biotechnology Corporation announced two presentations demonstrating that the extent of the immunological response triggered by its novel proprietary cancer immunotherapeutic AE37 vaccine correlated with a reduction of relapse in breast cancer patients. The presentations are being made at the American College of Surgeons Clinical Congress 2014, being held October 26--30, 2014 in San Francisco, CA. The AE37 cancer vaccine is designed to elicit a specific immunological response targeting the HER2 cancer-associated protein. The Company previously reported a strong trend toward reduced relapse in patients with lower levels of HER2 expression who received the AE37 vaccine; i.e., in patients who are not eligible for the drug Herceptin (which also targets the HER2 protein). In particular, the most favorable results were observed in patients with triple negative breast cancer. Patients with this type of cancer are not eligible for either Herceptin or hormone therapy and thus constitute one of the areas of unmet need among breast cancer patients. The first study, entitled "Biomarker Correlation to Clinical Response in a phase II Trial of the HER2 Peptide Vaccine (AE37+GM-CSF)", by Schneble et al, is being given as a podium presentation. In that study, the extent of the local reaction to the vaccine as well as the presence of specific T cells in the blood that had been specifically activated by AE37 was measured. The study found that for patients who had a more robust response to the vaccine there was a significantly reduced incidence of relapse compared to those who developed weaker responses. The second presentation, entitled "Clinical benefit and safety of boosting the HER2 peptide vaccine (AE37+GM-CSF) in the adjuvant setting to prevent breast cancer recurrence", also by Schnebel et al, assessed the impact of AE37 booster immunizations on reducing the risk of recurrence. The study concludes that the trend toward reduced relapse is strongest in patients who have received boosters. Taken together, the newly reported studies provide important new data correlating immunological response to AE37 with clinical response. The new studies are based on patient data from a controlled, randomized and single-blinded phase II trial assessing the efficacy of the AE37 vaccine in patients with early stage breast cancer. The conclusions corroborate prior results from a phase I trial of AE37 in patients with prostate cancer. Immunological response data from that trial similarly showed a trend toward improved disease-free and overall survival in patients who developed a more robust response to the AE37 vaccine.

Generex Biotechnology Corp. Presents at BIO-Europe 2014, Nov-03-2014

Generex Biotechnology Corp. Presents at BIO-Europe 2014, Nov-03-2014 . Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNBT:US $0.01 USD -0.0004

GNBT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GNBT.
View Industry Companies
 

Industry Analysis

GNBT

Industry Average

Valuation GNBT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENEREX BIOTECHNOLOGY CORP, please visit www.generex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.